AR082353A1 - Ligando ox40 y de linfopoyetina del estroma timico (tslp) en el cancer - Google Patents
Ligando ox40 y de linfopoyetina del estroma timico (tslp) en el cancerInfo
- Publication number
- AR082353A1 AR082353A1 ARP110102697A ARP110102697A AR082353A1 AR 082353 A1 AR082353 A1 AR 082353A1 AR P110102697 A ARP110102697 A AR P110102697A AR P110102697 A ARP110102697 A AR P110102697A AR 082353 A1 AR082353 A1 AR 082353A1
- Authority
- AR
- Argentina
- Prior art keywords
- tslp
- antibody
- cancer
- subject
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Una composición terapéutica para el tratamiento de un tumor de origen epitelial en un sujeto humano, caracterizada porque comprende: uno o más agentes activos que se unen y neutralizan la actividad de una linfopoyetina del estroma tímico (TSLP), en donde dichos uno o más agentes activos se seleccionan del grupo que consiste de un anticuerpo anti-TSLP, un fragmento de un anticuerpo anti-TSLP, un conjugado de anticuerpo anti-TSLP-vehículo, una proteína de fusión de unión a TSLP, un antagonista de TSLP, un inhibidor de TSLP, un antagonista del receptor de TSLP o un agente bloqueante de TSLP opcionalmente solubilizado, disperso o suspendido en un medio adecuado en una cantidad suficiente para inhibir el desarrollo del tumor.Reivindicación 9: Uso de una composición farmacéutica caracterizada porque es para la fabricación de un medicamento para tratar o aliviar síntomas de un cáncer de origen epitelial en un sujeto humano, donde el tratamiento comprende los pasos de: identificar al sujeto que necesita tratamiento contra el cáncer; y administrar una cantidad terapéuticamente eficaz de una composición farmacéutica suficiente para tratar o aliviar los síntomas del cáncer en el sujeto, que comprende uno o más anticuerpos monoclonales o policlonales seleccionados del grupo que consiste de un anticuerpo anti-OX40L, un anticuerpo anti-linfopoyetina del estroma tímico (TSLP) o ambos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36774310P | 2010-07-26 | 2010-07-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082353A1 true AR082353A1 (es) | 2012-11-28 |
Family
ID=45493808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102697A AR082353A1 (es) | 2010-07-26 | 2011-07-26 | Ligando ox40 y de linfopoyetina del estroma timico (tslp) en el cancer |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20120020960A1 (es) |
| AR (1) | AR082353A1 (es) |
| TW (1) | TW201206471A (es) |
| WO (1) | WO2012015696A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2981280A2 (en) | 2013-04-04 | 2016-02-10 | IEO - Istituto Europeo di Oncologia Srl | Thymic stromal lymphopoietin fragments and uses thereof |
| PT3031913T (pt) * | 2013-08-09 | 2019-05-31 | Astellas Pharma Inc | Novo anticorpo anti-receptor de tslp humana |
| EP3194445A4 (en) | 2014-08-04 | 2018-05-23 | Baylor Research Institute | Antagonistic anti-ox40l antibodies and methods of their use |
| TWI787161B (zh) | 2015-12-18 | 2022-12-21 | 日商安斯泰來製藥股份有限公司 | 含有抗人類ｔｓｌｐ受體抗體之醫藥組成物 |
| KR102047502B1 (ko) * | 2016-06-20 | 2019-11-22 | 셀라이온바이오메드 주식회사 | 포타슘 채널 단백질을 이용한 암 진단용 조성물 |
| WO2022079036A1 (en) * | 2020-10-13 | 2022-04-21 | Almirall, S.A. | Bispecific molecules and methods of treatment using the same |
| CN114369654B (zh) * | 2021-12-21 | 2023-11-07 | 广州市妇女儿童医疗中心 | 川崎病的生物标志物及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2313076T3 (es) * | 2003-07-18 | 2009-03-01 | Schering Corporation | Tratamiento y diagnostico de neoplasias usando linfopoyetina estromal timica. |
| US20050249712A1 (en) * | 2004-03-23 | 2005-11-10 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Methods for use of TSLP and agonists and antagonists thereof |
| US20060039910A1 (en) * | 2004-08-20 | 2006-02-23 | Amgen Inc. | Methods and compositions for treating allergic inflammation |
| WO2007133290A2 (en) * | 2005-12-16 | 2007-11-22 | Genentech, Inc. | Anti-ox40l antibodies and methods using same |
| BRPI0820875B1 (pt) * | 2007-12-14 | 2021-10-19 | Bristol-Myers Squibb Company | Molécula de ligação isolada, anticorpo monoclonal humano, composição, molécula de ácido nucleico, vetor e célula hospedeira |
-
2011
- 2011-07-22 US US13/189,244 patent/US20120020960A1/en not_active Abandoned
- 2011-07-22 WO PCT/US2011/045041 patent/WO2012015696A1/en active Application Filing
- 2011-07-26 AR ARP110102697A patent/AR082353A1/es unknown
- 2011-07-26 TW TW100126469A patent/TW201206471A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012015696A1 (en) | 2012-02-02 |
| US20120020960A1 (en) | 2012-01-26 |
| TW201206471A (en) | 2012-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082353A1 (es) | Ligando ox40 y de linfopoyetina del estroma timico (tslp) en el cancer | |
| PH12019502484A1 (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| CY1121148T1 (el) | Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων | |
| NZ590131A (en) | Notch-binding agents and antagonists and methods of use thereof | |
| EA201590144A1 (ru) | Rspo3-связывающие агенты и их применение | |
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
| AR104812A1 (es) | Combinaciones terapéuticas y métodos para tratar neoplasias | |
| MX2014000555A (es) | Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos. | |
| EA201490957A1 (ru) | Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| BR112016012506A8 (pt) | combinações farmacêuticas, seus usos, e uso de um portador de dados | |
| NZ601580A (en) | Therapeutic methods using anti-cd200 antibodies | |
| BR112015003459A2 (pt) | moléculas com atividade de ligação ao antígeno e de ligação ao receptor fc gama polivalente | |
| ES2675779T3 (es) | Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R | |
| EA201390506A1 (ru) | Полипептиды, которые связывают компонент с5 комплемента человека | |
| MX2023002554A (es) | Anticuerpos anti-il-1r3 humanizados. | |
| RU2014134923A (ru) | Антагонисты alk1 и их применение в лечении почечно-клеточного рака | |
| EA201690321A1 (ru) | Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей | |
| Novello et al. | Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non–small-cell lung cancer: results from the randomized controlled MONET1 study | |
| EA201491352A1 (ru) | Способ лечения рака груди | |
| BR112022001037A2 (pt) | Métodos para tratamento ou prevenção de cânceres envolvendo a administração de agentes receptores anti-ccr5 | |
| MX2021012406A (es) | Combinaciones de anticuerpos anti-ildr2 y antagonistas de pd-1. | |
| MX2022014275A (es) | Uso de inhibidores del factor d del complemento solos o junto con anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna. | |
| EA202191388A1 (ru) | Лечение головной боли при избыточном применении лекарственных препаратов антителами к cgrp или cgrp-r | |
| EA202092481A1 (ru) | Комбинированный способ лечения антагонистом cd73 и антагонистом оси pd-1/pd-l1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |